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Aims

It is thought that clopidogrel bioactivation and antiplatelet response are related to cytochrome P450 2C19
(CYP2C19). However, a recent study challenged this notion by proposing CYP2C19 as wholly irrelevant, while identifying paraoxonase-1 (PON1) and its Q192R polymorphism as the major driver of clopidogrel bioactivation and efficacy. The aim of this study was to systematically elucidate the mechanism and relative contribution of PON1 in
comparison to CYP2C19 to clopidogrel bioactivation and antiplatelet response.
.....................................................................................................................................................................................
Methods
First, the influence of CYP2C19 and PON1 polymorphisms and plasma paraoxonase activity on clopidogrel active
and results
metabolite (H4) levels and antiplatelet response was assessed in a cohort of healthy subjects (n ¼ 21) after administration of a single 75 mg dose of clopidogrel. There was a remarkably good correlation between H4 AUC (0–8 h)
and antiplatelet response (r 2 ¼ 0.78). Furthermore, CYP2C19 but not PON1 genotype was predictive of H4 levels
and antiplatelet response. There was no correlation between plasma paraoxonase activity and H4 levels. Secondly,
metabolic profiling of clopidogrel in vitro confirmed the role of CYP2C19 in bioactivating clopidogrel to H4. However,
heterologous expression of PON1 in cell-based systems revealed that PON1 cannot generate H4, but mediates the
formation of another thiol metabolite, termed Endo. Importantly, Endo plasma levels in humans are nearly 20-fold
lower than H4 and was not associated with any antiplatelet response.
.....................................................................................................................................................................................
Conclusion
Our results demonstrate that PON1 does not mediate clopidogrel active metabolite formation or antiplatelet action,
while CYP2C19 activity and genotype remains a predictor of clopidogrel pharmacokinetics and antiplatelet response.

----------------------------------------------------------------------------------------------------------------------------------------------------------Keywords

CYP2C19 † PON1 † Clopidogrel † Pharmacokinetics † Pharmacogenetics † Antiplatelet response

Introduction
Antiplatelet therapy is an important therapeutic intervention for
prevention of ischaemic events in patients with high-risk cardiovascular disease, particularly for those who undergo percutaneous
coronary intervention (PCI).1 Currently, the standard of care for
managing such patients is dual antiplatelet therapy with a P2Y12 receptor antagonist and the cyclooxygenase I inhibitor aspirin.
Clopidogrel is the most widely prescribed thienopyridine that

exerts its pharmacological effect by irreversibly binding to P2Y12
receptors on platelets, thereby diminishing adenosine diphosphate
(ADP)-mediated platelet aggregation.2 Although benefits from clopidogrel have been widely documented in large clinical trials,
marked interpatient variation in platelet responsiveness has
meant that 21% of the patients remain at risk for coronary
artery and stent thrombosis.3
Clopidogrel is a prodrug and its clinical efficacy appears to be a
function of the amount of enzymatically derived active thiol
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Methods
Clinical study design
The study was approved by the Research Ethics Board at the University of Western Ontario. All subjects (age 18 – 65) were non-smokers,
not taking concomitant medications, without previous exposure to
clopidogrel, and deemed healthy per medical exam. Healthy volunteers
who met the eligibility criteria were enrolled upon provision of written
informed consent (n ¼ 21; see Supplementary material online,
Table S1).
Overnight fasted subjects received a single oral dose of clopidogrel
(75 mg). In addition, 100 mg of midazolam was administered orally as
an in vivo probe for CYP3A4 activity. For pharmacokinetic analysis,
blood samples were collected over an 8 h period. Clopidogrel thiol
metabolites were stabilized for analysis using EDTA tubes containing
50 mL of 125 mM 2-bromo-3-methoxyacetophenone (MPB) (SigmaAldrich, Oakville, Canada).
To determine antiplatelet response, blood was collected using a
1.8 mL sodium citrate (3.2%) tube at baseline and 4 h post-clopidogrel
dose and subjected to the VerifyNow P2Y12 assay (Accumetrics, San
Diego, CA, USA), as per the manufacturer’s protocol.
Genotype analysis and plasma paraoxonase activity were determined as described in Supplementary material online.

Clopidogrel bioactivation
The in vitro metabolic profiling of clopidogrel metabolism was conducted in microsomes (see Supplementary material online).

Liquid chromatography tandem mass
spectrometry (LC– MS/MS) analysis
Quantitation of midazolam and clopidogrel metabolites (in vivo and
in vitro) was performed as described in Supplementary material online.

Data analysis
All data analyses are as described in Supplementary material online.

Results
Influence of CYP2C19, PON1, and
CYP3A4 on clopidogrel kinetics
and response
Following a 75 mg dose, carriers of at least one reduced function
CYP2C19 allele [CYP2C19*2 or *3 allele, reduced metabolizers
(RMs); 38% of the study population] had significantly decreased
total plasma exposure (area under the plasma concentration
curve, AUC) of the H4 active metabolite when compared with
the non-carrier extensive metabolizers (EMs) (Figure 1A; see Supplementary material online, Figure S1A). Similarly, the maximum
plasma concentration (Cmax) was higher in EMs than RMs
(Table 1). Prior to administration of clopidogrel, the mean platelet
responsiveness [platelet reactive units (PRU)] induced by 20 mmol/
L ADP and 22 nM prostaglandin E1 (PGE1) was similar between
EMs and RMs (VerifyNow P2Y12 assay; Table 2). Four hours following clopidogrel administration, the absolute percentage change in
PRU was significantly lower in RMs when compared with EMs
(Figure 1B). In fact, we observed a strong correlation between
H4 plasma exposure and platelet inhibition, demonstrating that
individuals with highest exposure to H4 active metabolite have
the greatest antiplatelet response (Figure 1C). Interestingly, we
did not observe any correlation between gain-of-function PON1
Q192R polymorphism and clopidogrel pharmacokinetics or response, despite the fact that PON1 plasma activity, assessed ex
vivo using paraoxon as the prototypical substrate, in the same
healthy volunteers correlated well with the PON1 Q192R genotype (Figure 1D and E; see Supplementary material online, Figure
S1B). In addition, no significant correlation was found between
paraoxonase plasma activity and antiplatelet response (Figure 1F).
Of note, exclusion of non-Caucasian participants in these analyses
does not modify the above findings (data not shown).
Midazolam plasma AUC was not related to H4 AUC or antiplatelet response (P ¼ 0.91, 0.65) (Figure 2).

Identification of other clopidogrel thiol
metabolites in plasma
Using an ultra-high-performance liquid chromatography –tandem
mass spectrometry (UHPLC–MS/MS) method, we were able to
detect and quantify other clopidogrel thiol metabolites isobaric
to H4 in the plasma of study subjects (Figure 3A).9 One metabolite,
known to be inactive is termed H3, is stereochemically similar to
H4 except being diastereomeric at the carbon 4 position.
Another observed thiol metabolite is termed Endo, which differs
from H3/H4, in that the carbon double bond is in the endocyclic
position. In addition to chromatographic separation of H3, H4,
and Endo (Figure 3C and E), the MS fragmentation signatures of
the H3/H4 and Endo thiol metabolite were distinct (Figure 3D
and F ), ensuring analytical specificity of the isomers being analysed.
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metabolite formed.4,5 Previous in vitro studies have delineated that
this bioactivation is a two-step process, catalysed by several cytochrome P450 (CYP) isozymes.6 – 8 Clopidogrel is first metabolized
to the intermediate metabolite, 2-oxo-clopidogrel, followed by
metabolism to a number of thiol metabolite stereoisomers, only
one of which (H4) is active in vivo.2,5,9 Notably, both metabolic
steps leading to H4 formation have been shown to be predominantly dependent on CYP2C19 and, to a lesser extent, CYP3A4.6 Importantly, in large clinical trials, CYP2C19*2 or *3 loss-of-function
single-nucleotide polymorphisms (SNPs) have been associated
with lower platelet inhibition and, consequently, an increased risk
of major cardiovascular events.10 – 12
In contrast, Bouman et al. 13 recently demonstrated that a
non-CYP enzyme, paraoxonase-1 (PON1), was the key determinant of clopidogrel active metabolite formation. Importantly, they
showed that plasma PON1 activity as well as the Q192R SNP
(rs662) in PON1, but not CYP2C19 SNPs, was predictive of antiplatelet response and risk for stent thrombosis in clopidogrel-treated
patients. These findings fundamentally challenged our prior understanding of clopidogrel metabolism and efficacy. In the report, we
set out to define a mechanistic link between clopidogrel metabolism and antiplatelet action to clarify the clinical relevance of PON1
and CYP2C19 to clopidogrel response.
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Box-and-whisker plots of total active metabolite H4 plasma exposure (AUC) and antiplatelet response according to CYP2C19 genotype. (C)
Scatter plot of H4 AUC and antiplatelet response (r 2 ¼ 0.78). (D and E) Box-and-whisker plots of H4 AUC, paraoxonase plasma activity,
and antiplatelet response according to the PON1 genotype. (F ) Scatter plot of plasma paraoxonase activity and antiplatelet response. Boxes
indicate 25th and 75th percentile, whiskers denote the 95% confidence interval, and ‘+’ represents the mean. *P , 0.05; **P , 0.01.

Biotransformation of clopidogrel
to 2-oxo-clopidogrel

Biotransformation of 2-oxo-clopidogrel
to Endo thiol metabolite

In the first step of the bioactivation process, the intrinsic clearances
(CLint) calculated from estimated Km and Vmax values show that
CYP2C19 is more efficient in forming the intermediate metabolite
than CYP3A4 in vitro (Figure 4A; see Supplementary material online,
Table S2).

We incubated a range of 2-oxo-clopidogrel concentrations with
baculovirus microsomes heterologously expressing CYP2C19 and
HeLa cell-derived microsomes constitutively expressing PON1
while lacking any drug-metabolizing CYP enzymes. In the baculovirus microsomes, Endo metabolite formation was greater with
CYP2C19 than in control baculovirus microsomes (Figure 4C; see
Supplementary material online, Table S3). In addition, HeLa cell
microsomes constitutively expressing PON1 were capable of
forming Endo metabolite but not H4 (Figures 3B and 4D; see Supplementary material online, Table S3). We further confirmed the
ability of PON1 to hydrolyse 2-oxo-clopidogrel using an adenovirus overexpressing system in HeLa cells, where Endo formation
was 3.5-fold higher than vector control (LacZ) and no H4 was
detected (Figure 4E). Moreover, Endo formation by PON1 was
attenuated by the specific PON1 inhibitor 2-hydroxyquinoline
(Figure 4E). We note that PON1-mediated Endo formation was
not dependent on GSH (data not shown). Overall, our data suggests that PON1 can hydrolyse 2-oxo-clopidogrel to form Endo
metabolite while unable to mediate H4 formation and that
CYP2C19 also catalyses Endo formation. Analysis of total Endo

Biotransformation of 2-oxo-clopidogrel
to H3 and H4 thiol metabolites
In the second step of the bioactivation process, the CLint for H4
formation from 2-oxo-clopidogrel by CYP2C19 was greater than
that with CYP3A4 (Figure 4B; see Supplementary material online,
Table S2). Notably, the formation of H4 from 2-oxo-clopidogrel
was dependent on the presence of 5 mM reduced glutathione
(GSH) (data not shown). Based on lower H4 formation compared
with 2-oxo-clopidogrel formation, it appears that the second reaction is the rate-limiting step of the overall clopidogrel bioactivation.
We observed that the inactive metabolite, H3, was also formed
from 2-oxo-clopidogrel by CYP2C19 at a relatively similar efficiency as H4 (see Supplementary material online, Table S2).
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Figure 1 The role of CYP2C19 and PON1 genetic polymorphisms in clopidogrel pharmacokinetic and pharmacodynamic responses. (A and B)
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Table 1 H4 active metabolite pharmacokinetic
parameters following administration of a single 75 mg
oral dose of clopidogrel

Table 2 Platelet response pre- and 4 h
post-clopidogrel administration
P-value

P-value

................................................................................
Cmax (ng/mL)

33.9 (21.0)

CYP2C19
EM
RM

40.2 (23.3)
25.5 (13.7)

0.05

PON1
30.34 (19.80)
41.84 (30.67)

R192R

27.70 (6.08)

0.55

Pre-dose PRU
CYP2C19
EM

348 (32)

RM
PON1

315 (43)

Q192Q

343 (41)

Q192R
R192R

306 (34)
361 (29)

................................................................................

Antiplatelet response (absolute % change PRU)

0.73 (0.18)

CYP2C19

0.77 (0.16)

EM
RM

RM

0.67 (0.17)

PON1
Q192Q

0.78 (0.16)

Q192R

0.68 (0.19)

R192R

0.65 (0.13)

0.18

CYP2C19
EM
RM

0.67 (0.19)

0.68 (0.19)
0.63 (0.25)

Q192R

0.69 (0.20)

R192R

0.67 (0.16)

RM

Q192Q
Q192R

15.4 (13.4)
24.8 (28.2)

R192R

14.51 (4.5)

0.55

EM, extensive metabolizer; RM, reduced metabolizer; PRU, platelet reactive units.
Data are represented as mean with standard deviation.

0.91

0.77

................................................................................
CYP2C19
EM

0.02

PON1

0.67 (0.20)

PON1
Q192Q

AUC0 – 8h (ng h/mL)

24.5 (19.0)
11.31 (14.82)

0.33

................................................................................
t1/2 (h)

0.07

................................................................................

tmax (h)
CYP2C19
EM

0.30

37.40 (21.97)
44.79 (25.09)
27.54 (12.27)

PON1
Q192Q

35.31 (21.57)

Q192R

43.27 (28.33)

R192R

27.47 (6.64)

0.03

0.66

Cmax, maximum plasma concentration; EM, extensive metabolizer (CYP2C19
*1/*1 or *1/*17); RM, reduced metabolizer (*1/*2, *2/*2 or *1/*3); tmax, time to
Cmax; t1/2, half-life; AUC0 – 8h, area under the plasma concentration curve. Data are
represented as mean with standard deviation.

plasma exposure in healthy volunteers demonstrated that its levels
were more than 20-fold lower than H4 (data not shown), and
unlike H4 (Figure 1C), Endo AUC did not correlate with antiplatelet
response (Figure 4F).

Discussion
The impact of CYP2C19 genetic variations on clopidogrel antiplatelet response has been documented in a number of studies.11,14 In
fact, a recent meta-analysis reported that carriers of CYP2C19*2

allele had a higher risk for major adverse cardiovascular events,
increased mortality, and stent thrombosis compared with noncarriers, independent of baseline cardiovascular risk.14 We note
that in contrast to these studies, one trial (CURE) reported
similar clopidogrel efficacy irrespective of the CYP2C19 genotype.15
A potential explanation for the disparate findings is the difference
in rate of PCI with stenting, where only 14.5% of the population
underwent stenting in the CURE trial while majority of patients
underwent stenting in other CYP2C19-supportive trials. Indeed, it
has been consistently shown that the greatest clinical benefit
with clopidogrel use is the reduction in stent thrombosis rate.16
Moreover, several prospective trials have restored diminished H4
exposure and poor antiplatelet response in CYP2C19 variant carriers by increasing clopidogrel dose, including one recently published multicentre double-blinded randomized clinical trial.17 – 19
However, our understanding of clopidogrel response in the
context of pharmacogenomics was further complicated when
Bouman et al. 13 challenged the aforementioned findings by identifying the PON1 Q192R polymorphism as the only genetic marker
associated with stent thrombosis, accounting for 72.5% of the response variation.
In the present study, we aimed to determine the influence of
CYP2C19 and PON1 on clopidogrel metabolism and antiplatelet
response. In contrast to Bouman et al., our results support the
notion that decreased CYP2C19 function reduces the formation
of clopidogrel active thiol metabolite, while PON1 showed no
effect on active metabolite exposure. It should be noted that
there are several challenges to accurate quantification of the
active metabolite, H4. First, H4 is one of several diastereomeric
thiol metabolites of clopidogrel observed during in vitro
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................................................................................
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metabolomic analysis that requires analytical techniques capable of
distinguishing the related species.5,9 Secondly, due to the reactive
nature of the free thiol metabolites, derivatization using alkylating
agents, such as MPB, has been required to trap the metabolite
for quantitation.9 In the current study, we followed a recently published stereoselective UHPLC–MS/MS method to determine
plasma concentrations of clopidogrel thiol metabolites (H4, H3,
and Endo) in our cohort.9 In the study by Bouman et al.,13 stereospecific separation of H3, H4, and Endo was not demonstrated,
thus resulting in inaccurate clopidogrel pharmacokinetic analysis.
Furthermore, they used an alternative method of stabilizing the
active metabolite for quantitation, and thus, these technical discrepancies may in part explain the discordant findings with
regards to contribution of CYP2C19 and PON1 to clopidogrel
pharmacokinetics.
Similar to a number of recent studies that refuted a clinically relevant role of PON1 genotypes to clopidogrel response, we show that
CYP2C19 but not PON1 genotype is related to ADP-induced antiplatelet response.20 – 22 This agrees well with a recently published
genome-wide association study in a healthy Amish population,
showing that the CYP2C19*2 allele had a significant association
with clopidogrel platelet aggregation, while the PON1 genotype
did not.23 The strong correlation between H4 exposure and antiplatelet response (r 2 ¼ 0.78) presented here suggests that known
genetic variation in CYP2C19 as well as interpatient variation in
expression and activity of this enzyme likely account for clopidogrel
resistance observed in non-responders.
The role of CYP3A4 in clopidogrel pharmacokinetics and
pharmacodynamics remains unclear. While some studies postulate
that CYP3A4 genotype and inhibition modulates clopidogrel
pharmacokinetics and action,24 many others do not.25 Midazolam
has been well documented as an in vivo probe drug for CYP3A4
activity.26 Thus, administration of a microdose of midazolam was
used here to measure CYP3A4 phenotype in subjects. To the
extent of our knowledge, we demonstrate for the first time that

CYP3A4 activity, as measured by midazolam exposure, is not an
important driver of clopidogrel pharmacokinetics or antiplatelet
response.
Recently, a correspondence from Dansette et al. questioned the
validity of the original findings of Bouman and colleagues.27 Specifically, they report that the Endo metabolite, but not other thiol
metabolites, is formed in human liver microsomes incubated with
2-oxo-clopidogrel in the absence of CYP-requiring NADPH. This
Endo formation was attenuated in the presence of the PON1 substrate paraoxon but unaffected by the presence of a CYP inhibitor.
Moreover, Dansette and colleagues found that the Endo metabolite was generated in serum (devoid of CYP enzymes) upon ex vivo
incubation with 2-oxo-clopidogrel. Those results indicate a role for
PON1 in the formation of the Endo metabolite but not in the
bioactivation to H4. The results from the current study not only
confirm the findings of Dansette et al., but solidify PON1 as the
key player in Endo but not H4 generation through systematic
and definitive metabolic experiments that include a PON1 overexpression system and recombinant CYP enzymes.
We believe that lack of analytical specificity, followed by misidentification of the synthesized analytical standard used to quantify clopidogrel active metabolite levels, may have been the
critical missteps which led to the conclusion by Bouman et al.
that PON1 generates the active metabolites.13 First, the conditions
for the separation of H4 from other structurally similar, but inactive metabolites requires high-resolution chromatographic
techniques such as UHPLC coupled with MS/MS. The liquid chromatographic method used by Bouman et al. was likely insufficient
for discriminating between active H4 from the inactive H3 and
Endo metabolites. It is also not certain whether the analytical
method used could quantify non-Endo thiol metabolites such as
H4. Secondly, Bouman et al. obtained their thiol metabolite
reference standard from purification of PON1-mediated 2-oxoclopidogrel hydrolysis.13 They suggest that this product was
active based on platelet reactivity experiments. However, those
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Figure 2 The role of CYP3A4 activity in clopidogrel pharmacokinetics and pharmacodynamics. (A and B) Scatter plot of total midazolam
plasma exposure and H4 active metabolite exposure, or antiplatelet response, respectively.
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Figure 3 Representative chromatograms of derivatized H4 and Endo metabolite. (A) Chromatogram of a human plasma sample derivatized
with 2-bromo-3-methoxyacetophenone. (B) Chromatogram of a sample derived from PON1-mediated hydrolysis of 2-oxo-clopidogrel.
(C and D) Chromatogram of Endo standard and its MS/MS fragmentation signature. (E and F) Chromatogram of H4 standard and its
tandem mass spectrometry fragmentation signature.

experiments were performed at purified thiol metabolite concentrations of 2 mg/L, which is 100 times greater than the reported
plasma thiol metabolite concentration. Since we clearly show

that PON1 can only generate Endo and not H4, it is clear that
the thiol metabolite they had used as analytical standard to represent the active metabolite was in fact the inactive Endo metabolite.
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Figure 4 Clopidogrel bioactivation in vitro. (A) Formation of 2-oxo-clopidogrel by CYP2C19 and CYP3A4. (B) Formation of H4 active metabolite by CYP2C19 and CYP3A4. (C) Formation of the Endo metabolite by CYP2C19 and CYP-lacking baculovirus insect-cell microsomes.
(D) 2-Oxo-clopidogrel metabolism to Endo metabolite by HeLa cell line-derived microsomes. (E) PON1-mediated hydrolysis of 2-oxoclopidogrel to the Endo metabolite in the absence or presence of PON1 inhibitor, 2-hydroxyquinoline. Symbols and bars represent means
and standard errors. (F ) Scatter plot of Endo metabolite plasma exposure and antiplatelet response. *P , 0.001.

Bouman and colleagues admit that their analytical methods did not
distinguish between different thiol metabolites derived from
PON1, human liver microsomes, or human serum in vitro.27 They

argue that the ratio of produced active thiol metabolites to total
thiol metabolites was constant between enzyme preparations
based on platelet reactivity studies of purified thiols, suggesting

CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation
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that PON1 creates a similar degree of active metabolites as human
liver microsomes. Again, it is important to note that those platelet
incubations were performed at purified thiol metabolite concentrations of 0.5 –5 mg/L, values that are 25 –250 times greater
than their reported concentration of thiol metabolites patient
plasma, bringing to question the relevance of such experiments
as an argument for not requiring greater analytical specificity.
Without identification and quantitation of these unknown PON1derived active metabolites in relation to the amount of H4 active
metabolite known to be found at significant levels in patient/
subject plasma, it would seem that Bouman and colleagues have
not clarified a role for PON1 in clopidogrel bioactivation.
Here, the in vitro data are consistent with previous studies that
demonstrated the importance of CYP isozymes in clopidogrel
bioactivation.6,7,27 In addition, the mechanism by which the 2-oxoclopidogrel ring opens to expose the free thiol in H4 metabolite
has been shown to be dependent on the presence of a reducing
agent such as GSH.7,8 Consistent with such data, we see a lack
of H4 formation by CYP enzymes in the absence of GSH.

Overall, we propose that both steps of clopidogrel bioactivation
are mainly driven by CYP2C19, ultimately generating active H4,
while PON1-mediated hydrolysis of 2-oxo-clopidogrel generates
the Endo metabolite (Figure 5). Notably, we show that the estimated enzyme affinity (Km) of 2-oxo-clopidogrel to CYP2C19 is
much higher than that of PON1, concordant with the low
2-oxo-clopidogrel affinity for PON1 demonstrated by Bouman
et al.13 Accordingly, in hepatocytes, where clopidogrel bioactivation occurs, CYP2C19-mediated oxidation of 2-oxo-clopiodgrel
would be the preferred pathway at therapeutic concentrations of
the drug. Importantly, to the extent of our knowledge, this is the
first study to quantify Endo and H4 concentrations simultaneously
in humans. We demonstrate that Endo levels are nearly 20-fold
lower compared with H4; thus, Endo is unlikely to contribute substantially to clopidogrel antiplatelet response, in addition to the
lack of association between Endo levels and antiplatelet response.
Moreover, these results are further substantiated by our findings of
no association between PON1 plasma activity and genotype with
H4 levels or antiplatelet activity.
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Figure 5 Schematic summary of clopidogrel bioactivation.
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correlation existed between plasma paraoxonase activity and
Endo levels to antiplatelet response. Accordingly, although it
remains likely that there are other genetic and non-genetic determinants of clopidogrel efficacy, our study suggests that CYP2C19
but not PON1 or CYP3A4 is a mechanistic determinant of interpatient antiplatelet response variability to clopidogrel therapy.

Supplementary material
Supplementary material is available at European Heart Journal
online.
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alleles of CYP2C19*2 or CYP2C19*3 into one group and cannot
comment on the differential influence of these alleles or its genedose effect on clopidogrel pharmacokinetics and pharmacodynamics. Such pooling of CYP2C19 variant carriers has been done previously for similar reasons.28 It should be noted that in terms of
sample size, an 80% power was achieved to detect a 40% difference in antiplatelet response between CYP2C19 EM and RM genotype groups with a two-sided significance level of 0.05, and a
standard deviation of 20%. With respect to PON1 analysis, the
high interindividual variability observed within PON1 genotype
groups lead to reduction in power below 80%. However, the
lack of PON1 Q192R genetic influence on clopidogrel response
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P2Y12 assay to measure clopidogrel antiplatelet response. While
VerifyNow utilizes ADP and PGE1 to induce and measure global
platelet aggregation, it is not as direct a measure of platelet
P2Y12 signalling activity as the vasodilator-stimulated phosphoprotein (VASP) assay or even direct receptor occupancy assays using
33
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